Alpha1Health.com | Options for your New AAT Deficient Patient | ARALAST Efficacy

ARALAST Efficacy1

Alpha1Health.com Survey

Take the Alpha1Health.com Survey

Take our survey to help us best meet the needs of the Alpha-1 community.

 

eLearning Program

AlphaTest® Kit

View our eLearning Program to learn more about Alpha-1

 

ARALAST replaces or augments the concentration of alpha1-proteinase inhibitor (A1-PI) in the blood of AAT-deficient patients. Ultimately, this leads to elevated concentrations of A1-PI in the epithelial lining fluid (ELF) of the lower respiratory tract.

In the ELF:

  • ARALAST increases A1-PI activity in the ELF ≈ 6- fold (mean rise: 1, 103 µM) at 7 weeks.

In serum:

  • ARALAST exceeds ATS/ERS standards for A1-PI serum concentrations by 31%. (The ATS/ERS considers 11 µM to be the "protective threshold," above which the lung appears to be able to protect itself adequately.2)

ARALAST [Alpha1-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

  1. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha (1)-antitrypsin, Respitin. Chest. 2002; 122:66-74.
  2. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003; 168:818-900.
adobe reader To view PDF, you will need Adobe® Acrobat® Reader® software.